Aurinia Pharmaceuticals (AUP) to Release Earnings on Thursday

Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) is set to announce its earnings results after the market closes on Thursday, November 8th. Analysts expect the company to announce earnings of C($0.23) per share for the quarter.

Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last released its earnings results on Thursday, August 9th. The company reported C($0.25) earnings per share for the quarter, missing the consensus estimate of C($0.21) by C($0.04). The firm had revenue of C$0.04 million for the quarter, compared to analyst estimates of C$0.07 million.

Aurinia Pharmaceuticals stock opened at C$7.48 on Wednesday. Aurinia Pharmaceuticals has a fifty-two week low of C$5.68 and a fifty-two week high of C$8.65.

TRADEMARK VIOLATION WARNING: “Aurinia Pharmaceuticals (AUP) to Release Earnings on Thursday” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/07/aurinia-pharmaceuticals-aup-to-release-earnings-on-thursday.html.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Story: Retained Earnings

Earnings History for Aurinia Pharmaceuticals (TSE:AUP)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply